<table>
<thead>
<tr>
<th>Title</th>
<th>Synergistic Costimulatory Effect of Chlamydia pneumoniae with Carbon Nanoparticles on NLRP3 Inflammasome-Mediated Interleukin-1 beta Secretion in Macrophages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Matsuo, Junji; Nakamura, Shinji; Takeda, Seiji; Ishida, Kasumi; Yamazaki, Tomohiro; Yoshida, Mitsutaka; Chiba, Hitoshi; Hui, Shu-Ping; Yamaguchi, Hiroyuki</td>
</tr>
<tr>
<td>Citation</td>
<td>Infection and immunity, 83(7): 2917-2925</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2015-07</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/60611">http://hdl.handle.net/2115/60611</a></td>
</tr>
<tr>
<td>Type</td>
<td>article (author version)</td>
</tr>
<tr>
<td>File Information</td>
<td>Infect Immun_83(7)_2917-2925.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers: HUSCAP
Synergistic costimulatory effect of *Chlamydia pneumoniae* with carbon nanoparticles on NLRP3 inflammasome-mediated IL-1β secretion in macrophages

Junji Matsuo¹, Shinji Nakamura², Seiji Takeda³, Kasumi Ishida¹,⁴, Tomohiro Yamazaki¹,⁴, Mitsutaka Yoshida⁵, Hitoshi Chiba³,⁶, Shu-Ping Hui¹,³, Hiroyuki Yamaguchi¹#

¹Department of Medical Laboratory Science, ³Health Innovation & Technology Center, and ⁶Department of Health Science Technology, Faculty of Health Sciences, Hokkaido University, Sapporo 060-0812, Japan

²Division of Biomedical Imaging Research, and ⁵Division of Ultrastructural Research, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan

⁴Research Fellow of Japan Society for the Promotion of Science, Kojimachi Business Center Building, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan

Running title: Stimulation of *Chlamydia* with Nanoparticles and IL-1β

#Address correspondence to Hiroyuki Yamaguchi, E-mail address: hiroyuki@med.hokudai.ac.jp
ABSTRACT

Obligate intracellular bacterium, *Chlamydia pneumoniae* is not only a causative agent of community-acquired pneumonia, but is also associated with a more serious chronic disease, asthma, which might be exacerbated by air pollution containing carbon nanoparticles. Although a detailed mechanism of exacerbation remains unknown, the proinflammatory cytokine interleukin (IL)-1β is a critical player in the pathogenesis of asthma. *C. pneumoniae* induces IL-1β in macrophages via NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome activation and toll-like receptor (TLR)2/4 stimulation. Carbon nanoparticles, carbon nanotubes (CNTs) can also evoke the NLRP3 inflammasome to trigger IL-1β secretion from lipopolysaccharide-primed macrophages. This study assessed whether co-stimulation of *C. pneumoniae* with CNTs synergistically enhanced IL-1β secretion from macrophages, and determined the molecular mechanism involved. Enhanced IL-1β secretion from *C. pneumoniae*-infected macrophages by CNTs was dose- and time-dependent. Transmission electron microscopy revealed that *C. pneumoniae* and CNTs were engulfed concurrently by macrophages. Inhibitors of actin polymerization or caspase-1, a component of the inflammasome, significantly blocked IL-1β secretion. Gene silencing using siRNA targeting *nlrp3* also abolished IL-1β secretion. Other inhibitors (K⁺ efflux inhibitor, cathepsin B inhibitor, reactive oxygen species generating inhibitor) also blocked IL-1β secretion. Taken together, these findings demonstrated that CNTs synergistically enhanced IL-1β secretion from *C. pneumoniae*-infected macrophages via the NLRP3 inflammasome and caspase-1 activation, providing a novel insight into our understanding of how *C. pneumoniae* infection can exacerbate asthma.
INTRODUCTION

*Chlamydia pneumoniae* is an obligate intracellular bacterium and a causative agent of respiratory tract infections including community-acquired pneumonia (1, 2). The seroprevalence rates of *C. pneumoniae* infection, which start to rise relatively early in childhood, are increased by 50% at 20 years of age, and subsequently reach 70–80% by 60–70 years (3, 4), suggesting most individuals will have had some exposure to the bacteria in their lifetime. Therefore, *C. pneumoniae* is likely a ubiquitous pathogen in individuals worldwide (4). The symptoms of pulmonary infection vary considerably according to age from asymptomatic or mild illness to serious pneumonia, especially in pediatric infection (1–3). Regarding this, several studies indicate that bacterial infection might exacerbate pulmonary inflammation, and thus is associated with a more serious chronic disease, asthma (3). The proinflammatory cytokine interleukin (IL)-1β, which is induced by *C. pneumoniae* (5–8), is thought to play a critical role in the development of chronic inflammatory disease, although detailed mechanisms remain unclear. Air pollution containing carbon nanoparticles, environmental air contaminants that might be easily inhaled with *C. pneumoniae*, also appear to be a critical factor in the pathogenesis of asthma (9–11). Recent studies indicated that carbon black or carbon nanotubes (CNTs), belonging to carbon nanoparticles, stimulate IL-1β secretion from lipopolysaccharide (LPS)-primed macrophages (12–14).

IL-1β secretion is strictly controlled by two different steps: (i) pro-IL-1β transcription, and (ii) the cleavage of pro-IL-1β by a caspase-1-containing protein complex, the inflammasome (15–17). First, pro-IL-1β is transcribed via NF-κB activation following signaling from pattern-recognition receptors (PRRs) such as toll-like receptors (TLRs) (signal 1). TLR signaling is initiated by binding to ligands, known as pathogen-associated molecular patterns (PAMPs) such as LPS, flagella, or lipoprotein (18). Then, pro-IL-1β is cleaved by the activated inflammasome, which consists of caspase-1, nucleotide-binding oligomerization
domain (NOD)-like receptor (NLR), and an adapter molecule, apoptosis-associated speck-
like protein containing a carboxy-terminal caspase recruitment domain (CARD) (ASC)
(signal 2). NLRs recognize PAMPs as well as danger-associated molecular patterns
(DAMPs), including nuclear DNA or RNA, and cytosolic proteins (18). Interestingly, while
IL-1β secretion from *C. pneumoniae*-infected cells requires both NF-κB activation via
TLR2/4 recognition (signal 1) and NLRP3 inflammasome activation (signal 2) (5, 19, 20),
LPS-primed macrophages stimulated with carbon nanoparticles activate the NLRP3
inflammasome (signal 2) (12–14). It is likely that while *C. pneumoniae* activates both signal
1 and 2, CNTs stimulates signal 2 alone. Thus, carbon nanoparticles are likely to be a
precipitating cause of NLRP3 inflammasome activation during *C. pneumoniae* infection.

In the present study, we assessed whether co-stimulation of *C. pneumoniae* with CNTs
synergistically enhanced IL-1β secretion from macrophages, and determined the molecular
mechanism involved.

**MATERIALS AND METHODS**

**Chemical reagents.** Phorbol 12-myristate 13-acetate (PMA), *Escherichia coli* LPS
(O55:B5), ATP, and N-acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (St.
Louis, MO). Pan-caspase inhibitor, Z-VAD-FMK and caspase-1 inhibitor, Z-WHED-FMK,
were also purchased from Peptide Institute (Osaka, Japan) and Enzo Life Sciences
(Farmingdale, NY), respectively. Other inhibitors, cytochalasin D and CA-074 Me,
bafilomycin A1, and diphenyleniodonium chloride (DPI) were also obtained from Enzo Life
Sciences (Farmingdale, NY), LC Laboratories (Woburn, MA), and Cayman Chemical (Ann
Arbor, MI), respectively.

**Cells.** HEp-2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Sigma) containing 10% heat-inactivated fetal calf serum (FCS) and antibiotics (gentamicin
sulfate, 10 µg/ml; vancomycin, 10 µg/ml; amphotericin B, 1 µg/ml) (Sigma) at 37°C in 5% CO₂. The human acute monocytic leukemia cell line, THP-1, was also cultured in RPMI 1640 (Sigma) containing 10% heat-inactivated FCS and antibiotics at 37°C in 5% CO₂.

**Bacteria.** *C. pneumoniae* TW183 was used in this study. The bacteria were propagated in HEp-2 cells as described previously (21). Infected cells were collected after 3 days incubation and then disrupted by freeze–thawing. After brief centrifugation at 180 × g for 5 min to remove cell debris, bacteria were concentrated at 9,000 × g for 10 min at 4 °C. Bacterial pellets were resuspended in sucrose–phosphate–glutamic acid buffer and stored at −80°C until use. The numbers of *C. pneumoniae* infectious progenies were determined as IFU (inclusion-forming units) by counting chlamydial inclusions formed in HEp-2 cells using fluorescein isothiocyanate (FITC)-conjugated monoclonal anti-*Chlamydia* antibody specific for *Chlamydia* LPS (Denka Seiken, Tokyo, Japan) as described previously (21).

**CNTs.** Single-wall CNTs 1.1 nm in diameter and 2,000–5,000 nm in length (Carbon Nanotechnologies Inc., TX., USA), were used as carbon nanoparticles in this study. CNTs were suspended in distilled water according to the method described previously (22), and stored at 4°C until use.

**Co-stimulation of *C. pneumoniae* with CNTs.** THP-1 cells (4 × 10⁶ cells/well) were seeded into a 6-well plate and allowed to differentiate into adherent macrophages in 10% FCS/RPMI 1640 supplemented with 50 nM PMA for 3 days. After washing with serum-free RPMI, PMA-stimulated THP-1 cells were suspended in serum-free Opti-MEM (Invitrogen, Carlsbad, CA) with antibiotics, and then incubated with *C. pneumoniae* at a multiplicity of infection (MOI) of 5. After 4 hours, the cells were further incubated with 30 µg/ml CNTs for 24 hours. Cells stimulated with 100 ng/ml *E. coli* LPS followed by 5 mM ATP were used as a positive control. IL-1β production from the supernatants and cell lysates was then determined by western blotting. In some experiments, cells were pre-incubated with 2 µM cytochalasin D.
(actin polymerization inhibitor), 100 nM bafilomycin A1 (vacuolar H-ATPase inhibitor), 10 μM Z-VAD-FMK (pan-caspase inhibitor), 10 μM Z-WHED-FMK (caspase-1 inhibitor), 70 mM KCl (K⁺ efflux inhibitor), 10 μM Ca-074 Me (cathepsin B inhibitor), 5 mM NAC (reactive oxygen species (ROS) inhibitor: antioxidant), or 10 μM DPI (ROS inhibitor: ROS generating pathway inhibitor) 1 hour prior to the inoculation of CNTs.

**Western blotting.** Culture supernatants were obtained from PMA-stimulated THP-1 cells. The supernatants were precipitated with 10% trichloroacetic acid (Sigma) for concentration by desalinization, washed with acetone, and then dried at room temperature. The dried pellets and remaining cells were suspended in a reducing sample buffer containing 2-mercaptoethanol. Samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were electrotransferred to polyvinylidene difluoride membranes (Millipore, Bedfold, MA) with a semi-dry electroblotter (Bio-Rad, Richmond, CA). Membranes were blocked with 1% (w/v) skimmed milk in Tris-buffered saline (TBS, pH 7.5) containing 0.05% Tween-20 (TBS-T) and incubated with mouse anti-IL-1β antibody (Cell Signaling Technology, Beverly, MA) or mouse anti-α-tubulin antibody (Cedarlane, Ontario, Canada) in Immuno-enhancer reagent A (Wako Pure Chemical Industries) overnight at 4°C. After washing with TBS-T, membranes were incubated with a horseradish-peroxidase-conjugated goat anti-mouse IgG antibody (Sigma) in Immuno-enhancer reagent B for 1 h at room temperature. Labeled proteins were visualized with ImmunoStar LD western blotting substrate (Wako Pure Chemical Industries) or western blotting substrate (Thermo Scientific, Waltham, MA).

**Quantitative (q)PCR.** Total RNA was extracted from stimulated or un-stimulated cells using High Pure RNA Isolation Kit (Roche, Indianapolis, IN) according to the manufacturer’s instructions. Extracted RNA was treated with DNA-free® (Ambion, Austin, TX, USA). cDNA was synthesized with random primers in ReverTra Ace® qPCR RT Master
Mix (Toyobo, Osaka, Japan). qPCR was performed with primers specific for IL-1β (forward: 5′-ACA GAG GAA GTG CTC CTT CCA-3′, reverse: 5′-GTC GGA GAT TCG TAG CTG GAT-3′), for IL-8 (forward: 5′-CTG CGC CAA CAC AGA AAT TA-3′, reverse: 5′-ATT GCA TCT GGC AAC CCT AC-3′), for tumor necrosis factor (TNF)α (forward: 5′-CCC CAG GGA CCT TCT CTC TCT AA-3′, reverse: 5′-TGA GGT ACA GGC CCT CTG AT-3′) (23), and for gapdh (forward: 5′-AAC GGG AAG CTC ACT GGC ATG-3′, reverse: 5′-TCC ACC ACC CTG TTG CTG TAG-3′) (24). PCR conditions consisted of 5 min denaturation at 95°C, followed by 40 cycles, each of 30 s denaturation at 95°C, 30 s annealing at 60°C, and 45 s extension at 72°C. The amount of mRNA expression of IL-1β, IL-8, or TNFα was normalized to that of gapdh. Whole DNA was also extracted from stimulated or un-stimulated cells using a High Pure PCR Template Preparation Kit (Roche), according to the manufacturer’s instructions. Extracted DNA was used for qPCR with pairs of primers specific for C. pneumoniae 16S rRNA (forward: 5′- GGT CTC AAC CCC ATC CGT GTC GG-3′; reverse: 5′- TGC GGA AAG CTG TAT TTC TAC AGT T-3′) (25) and host cellular gapdh (24). The thermal cycling conditions were 95°C for 5 min, followed by 40 cycles of 95°C for 30 s, 60°C for 30 sec, and 72°C for 45 s. The amount of amplified DNA of chlamydia 16S rDNA was normalized to that of gapdh DNA.

Transmission electron microscopy (TEM). PMA-stimulated THP-1 cells incubated with C. pneumoniae and CNTs were fixed with 3% glutaraldehyde (Sigma) in 0.1 M phosphate-buffered saline (PBS, pH 7.4) at 4°C. After washing with PBS, the cells were processed for alcohol dehydration and embedding in Epon 813, as described previously (21). Ultrathin sections of the cells were stained with lead citrate and uranium acetate before being viewed by electron microscopy.
Enzyme-linked immunosorbent assay (ELISA). IL-18 in culture supernatants from PMA-stimulated THP-1 cells was also measured with Human IL-18 ELISA Kit (MBL, Nagoya, Japan) according to the manufacturer’s protocol.

RNA interference. siRNA targeting nlrp3 (Sense 5′-GGU GUU GGA AUU AGA CAA Ctt-3’, antisense 5′-GUU GUC UAA UUC CAA CAC Ctt-3’) or control scrambled siRNA (Sense 5′-UUC UCC GAA CGU GUC ACG Utt-3’, antisense 5′-ACG UGA CAC GUU CGG AGA Att-3’) was used as described previously (19). One day before incubation with C. pneumoniae, siRNA or scrambled RNA was incubated with RNAiMAX (Invitrogen) according to the manufacturer’s instructions. Gene silencing of nlrp3 was confirmed with reverse transcription (RT)-PCR using primers specific for nlrp3 (forward: 5′-AGC CAC GCT AAT GAT CGA CT-3′, reverse: 5′-CAG GCT CAG AAT GCT CAT CA-3′) (27) and gapdh (24).

Statistical analysis. Statistical analysis was performed using an unpaired Student’s t test. A value of $p < 0.05$ was considered significant.

RESULTS

CNTs treatment enhanced IL-1β secretion from Chlamydia-stimulated macrophages. To assess our hypothesis, we first investigated whether CNT treatment could enhance IL-1β secretion from Chlamydia-stimulated macrophages using western blotting analysis. Mature IL-1β was clearly detected in supernatants from PMA-stimulated THP-1 cells incubated with C. pneumoniae for 24 hours, confirming previous reports (5–8). However, mature IL-1β was not detected in supernatants from cells stimulated with CNTs alone (Fig. 1A, Cpn and CNT). IL-1β secretion was significantly enhanced when cells were incubated with combined C. pneumoniae and CNTs (Fig. 1A, Cpn plus CNT). IL-1β
secretion also increased dependent upon time and dose (Fig. 1B and 1C, respectively). Thus, the results indicated a synergistic effect, whereby CNT treatment enhanced IL-1β secretion in C. pneumoniae-stimulated macrophages.

**CNTs treatment did not activate pro-IL-1β transcription in macrophages.** As mentioned above, IL-1β secretion is critically controlled by pro-IL-1β transcription via NF-κB activation and pro-IL-1β cleavage with inflammasome activation (15–17). We next investigated whether the synergistic effect of IL-1β maturation occurred at the mRNA expression level in C. pneumoniae-stimulated macrophages treated with CNTs using qRT-PCR. As shown in Fig. 2 (upper), while, IL-1β mRNA expression was significantly increased in THP-1 cells stimulated with either C. pneumoniae or C. pneumoniae plus CNTs, CNT treatment alone did not stimulate IL-1β mRNA expression. The transcription of mRNAs for other cytokines (IL-8 and TNFα), which are also regulated through NF-κB, were also increased by C. pneumoniae or C. pneumoniae plus CNTs (Fig. 2, middle and lower). Thus, CNT treatment induced IL-1β secretion from C. pneumoniae-stimulated THP-1 cells at the maturation level via NLRP3 inflammasome activation, rather than by IL-1β mRNA transcription.

**Synergistic effect of C. pneumoniae with CNTs on IL-1β secretion from macrophages does not require bacterial growth or de novo bacterial protein synthesis.** To assess whether the synergistic effect on IL-1β secretion required bacterial growth or de novo bacterial protein synthesis, bacterial growth with IL-1β secretion was monitored over 3 days in C. pneumoniae-stimulated macrophages treated with CNTs in the presence or absence of chloramphenicol, a protein synthesis inhibitor. qPCR analysis revealed no significant change in bacteria numbers during the culture period, even in the absence or presence of CNTs (Fig. 3A). The addition of chloramphenicol to the cultures had no influence on the synergistic effect of C. pneumoniae and CNTs on IL-1β secretion from macrophages (Fig.
Thus, the synergistic effect on IL-1β secretion from macrophages does not require either bacterial growth or de novo bacterial protein synthesis in cells.

**Synergistic effect of *C. pneumoniae* with CNTs on IL-1β secretion from macrophages requires uptake of bacteria and CNTs and is caspase-1-dependent.**

Through experiments with specific inhibitors cytochalasin D (actin polymerization inhibitor) and bafilomycin A1 (vacuolar H-ATPase inhibitor) and TEM observation, we assessed whether the synergistic effect required uptake of bacteria with CNTs or lysosomal maturation. In contrast to bafilomycin A1, treatment with cytochalasin D clearly blocked the synergistic effect on IL-1β secretion, likely via blocking *C. pneumoniae* infection (Fig. 4A). TEM observation revealed the coexistence of *C. pneumoniae* with CNTs in a macrophage (untreated with cytochalasin D) at 24 hours after incubation (Fig. 4B). Thus, the synergistic effect required the uptake of bacteria with CNTs into cells regardless of lysosomal maturation. Furthermore, because bacteria with CNTs stimulate the NLRP3 inflammasome to activate caspase-1 followed by IL-1β maturation (signal 2) (5, 19, 20), we also performed experiments using caspase inhibitors (Z-VAD-FMK: pan-caspase inhibitor; Z-WHED-FMK: caspase-1 inhibitor). Both inhibitors significantly blocked the synergistic effect on IL-1β secretion (Fig. 5A), and the inhibition was occurred in a dose-dependent manner of the caspase-1 inhibitor (Fig. 5B), indicating a requirement of caspase-1 activation for the synergistic effect. Thus, the synergistic effect of *C. pneumoniae* with CNTs on IL-1β secretion from macrophages requires both the uptake of bacteria with CNTs into cells and caspase-1 activation.

**Synergistic effect of *C. pneumoniae* with CNTs on IL-18 secretion from macrophages.** To confirm caspase-1 activation, we quantitatively measured the amount of IL-18 in supernatants as well as IL-1β cleaved by caspase-1 secreted from macrophages stimulated with either *C. pneumoniae* or *C. pneumoniae* plus CNTs by alternative method,
not western blotting, with commercial available ELISA kit (See the Materials and Methods). As expected, IL-18 secretion was significantly enhanced when incubated under combination of C. pneumoniae with CNTs (Fig. 6A). Furthermore, it was also confirmed that the IL-18 secretion was increased in a time-dependent manner (Fig. 6B). In addition, IL-18 and that the secretion as well as IL-1β maturation was significantly inhibited in a dose-dependent manner of the caspase-1 inhibitor (Fig. 6C). Thus, the results were supported by the evidence showing the synergistic effects of C. pneumoniae with CNTs into IL-1β maturation via caspase-1 activation.

Synergistic effect of C. pneumoniae with CNTs on IL-1β secretion from macrophages occurs via NLRP3 inflammasome activation. IL-1β maturation absolutely requires pro-IL-1β cleavage with caspase-1, following the construction of a large protein complex, the inflammasome, comprising caspase-1, NLR, and ASC (15–17). The inflammasome is commonly activated by bacterial infections including C. pneumoniae (5–8) or by stimulation with DAMPs (15, 16). Using siRNA to silence NLRP3 in cells (26), we assessed whether stimulation of C. pneumoniae with CNTs triggered NLRP3 inflammasome that is required for IL-1β secretion. The knockdown of nlrp3 mRNA expression was confirmed by RT-PCR (Fig. 7A). In contrast to scrambled siRNA, nlrp3-knockdown cells failed to show enhanced IL-1β secretion even under co-stimulation of C. pneumoniae with CNTs (Fig. 7B). Thus, stimulation with bacteria and CNTs enhanced NLRP3 inflammasome activation.

Synergistic effect of C. pneumoniae with CNTs on IL-1β secretion from macrophages requires upstream signals including K⁺ efflux, lysosomal degradation, and ROS production. It is well known that the NLRP3 inflammasome is fully activated by distinct upstream signals including K⁺ efflux (27), lysosomal degradation (28), and ROS production (29). We therefore investigated the upstream signal pathways required for NLRP3
inflammasome activation in cells stimulated by *C. pneumoniae* with CNTs, using specific inhibitors (KCl, K⁺ efflux inhibitor; CA-074 Me, cathepsin B inhibitor; NAC, ROS production inhibitor as an antioxidant; DPI, ROS production inhibitor as the generating pathway inhibitor). IL-1β secretion was clearly inhibited by treatment with KCl as compared with NaCl (control), indicating a requirement of K⁺ efflux (Fig. 8A). In addition, treatment with CA-074 Me obviously blocked IL-1β secretion, indicating that IL-1β secretion requires lysosomal degradation (Fig. 8B). Furthermore, treatment with DPI, but not NAC, inhibited IL-1β secretion, indicating IL-1β secretion partially requires ROS generation (Fig. 8C). Together, the results suggested that NLRP3 inflammasome activation coincidently requires three distinct upstream signals, K⁺ efflux, lysosomal degradation, and ROS production.

**DISCUSSION**

Seroepidemiological studies indicate *C. pneumoniae* infection has a high seroprevalence, indicating its ubiquitous distribution throughout the world (3, 4). While *C. pneumoniae* is a causative agent of pulmonary infection, symptoms of the infection vary from asymptomatic infection to serious pneumonia with high mortality (30). Furthermore, accumulated studies reveal an association of *C. pneumoniae* infection with chronic diseases such as asthma (3), which is evoked by air pollution containing carbon nanoparticles (9–11). However, the detailed mechanisms by which *C. pneumoniae* is involved in the development of asthma still remain unclear. We therefore studied the synergistic effect of *C. pneumoniae* with carbon nanoparticle derivatives, CNTs, on IL-1β secretion, to determine whether it exacerbated the mechanisms involved in *C. pneumoniae* infection. We found that CNTs synergistically enhanced IL-1β secretion from *C. pneumoniae*-infected macrophages.
In contrast to treatment with polymer such as dextran that enhances chlamydial growth in vitro (31), treatment with CNTs did not enhance *C. pneumoniae* growth in macrophages, excluding the possibility that the enhancement of infection by CNTs treatment is critical event on the synergistic effect. In addition, treatment with CNTs alone failed to induce IL-1β secretion (both mature and pro IL-1β) from/in macrophages, and no increase of inflammatory cytokine mRNA transcription (IL-1β, IL-8, TNFα) was observed in cells stimulated with CNTs alone. IL-1β secretion is strictly controlled by IL-1β mRNA expression and IL-1β cleavage in macrophages (15–17), therefore, evidence from previous studies and the current study indicate CNTs alone have no effects on IL-1β transcription via signaling through TLRs (stimulation by signal 2). In contrast to CNTs, treatment with the bacteria alone was sufficient to stimulate IL-1β transcription, and caspase inhibitors clearly blocked IL-1β maturation. Furthermore, previous studies also indicated that IL-1β transcription occurred in a TLR2/4-dependent manner in macrophages stimulated with *C. pneumoniae* alone (5–8, 19, 20, 32, 33). Thus, taken together, while CNTs only stimulate signal 2, *C. pneumoniae* stimulation can induce both signal 1 and 2, and stimulation from CNTs and *C. pneumoniae* independently can activate the NLRP3 inflammasome (signal 2).

Because the NLRP3 inflammasome is activated by distinct upstream signals including K⁺ efflux (27), lysosomal degradation (28), and ROS production (29), we attempted to determine the upstream signal pathway involved. We found that NLRP3 inflammasome activation required all three distinct upstream signals, K⁺ efflux, lysosomal degradation, and ROS production. Although antioxidant NAC failed to block the synergistic effect, ROS production may be partially involved in the effect. Further upstream signals including PAMPs derived from *C. pneumoniae* or CNTs require further study to determine their involvement. However, several studies have reported that type III secretion systems or their effectors are involved in NLRP3 inflammasome activation (34, 35), thus, these molecules might be
attractive candidates for inflammasome activation. Moreover, recent studies indicated that Chlamydia induces cell death at late stage infection with features of both apoptosis and necrosis (See Review 36). Oxidized mitochondrial DNA is also likely to be responsible for NLRP3 inflammasome activation and IL-1β secretion from C. pneumoniae-infected cells (37).

The current study indicates that full caspase-1 activation is important for C. pneumoniae-infected cell stimulation with CNTs. Although there was no direct evidence showing actual caspase-1 activation, our experiments using caspase inhibitors and significant increase of IL-18, which is another substrate of caspase-1 (15–17), support caspase-1 activation. Caspase-1 activation causes pyroptotic cell death by pore formation in plasma membranes (15, 38). We therefore confirmed whether cell death was induced by the stimulation of C. pneumoniae with CNTs using a pore forming assay, as previously described (39, 40). However, no obvious increase in pyroptotic cell death was observed (data not shown). A recent report has demonstrated two distinct pathways for NLRP3 inflammasome activation either with or without ASC activation (41). Therefore, IL-1β secretion from the C. pneumoniae-infected cells with CNTs treatment might occur in an ASC-independent manner, although further study is required to clarify this.

In conclusion, this study showed that CNTs synergistically activate the NLRP3 inflammasome in C. pneumoniae-infected macrophages inducing caspase-1 activation that enhances IL-1β secretion, providing a novel insight into the mechanism of how CNTs exacerbate C. pneumoniae infection. Regarding this, we propose a possible mechanism for IL-1β secretion from C. pneumoniae-infected cells with CNT treatment (Fig. 9). While C. pneumoniae activates both signal 1 and 2, CNTs stimulate signal 2 alone, together enhancing the cleavage of pro IL-1β cleavage to the mature form of IL-1β. To the best of our
knowledge, this is the first study to show a synergistic effect of *C. pneumoniae* with carbon nanoparticles on IL-1β secretion from immortal human macrophages.

ACKNOWLEDGMENTS

This study was supported by grants-in-aid for the Japan Society for the Promotion of Science (JSPS) KAKENHI, grant numbers 25860824, 21590474, 24659194, and 24117501 “Innovation Areas (Matryoshka-type evolution)”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
REFERENCES


kappaB but not through TRIF, interleukin-1 receptor 1 (IL-1R1)/IL-18R1, or toll-like receptors. Infect. immun. 79:4947–4956.


**FIG 1.** Representative western blotting images show synergistic effects of *Chlamydia pneumoniae* with CNTs on IL-1β secretion from macrophages. (A) Mature IL-1β secretion from macrophages is significantly increased by co-stimulation of *C. pneumoniae* with CNTs at 24 hours after incubation compared with CNTs or *C. pneumoniae* alone. B) Time-course experiment shows the synergistic increase of IL-1β secretion was time-dependent. (C) Dose-response experiment revealed that the synergistic increase of IL-1β secretion also occurred in a dose-dependent manner, dependent upon CNT concentration. Results are representative of three independent experiments. Tubulin was used as an internal control. sup, desalinized culture supernatants of THP-1 cells; cell, the remaining cells; Cpn, *C. pneumoniae*; CNT, carbon nanotube; LPS, lipopolysaccharide; IL, interleukin.

**FIG 2.** Increase of proinflammatory cytokine mRNA expression requires stimulation with either *Chlamydia pneumoniae* or *C. pneumoniae* plus CNTs, but not CNTs alone. Transcription of IL-1β, IL-8, or TNFα mRNA was determined by qRT-PCR, and the data (mean ± standard deviation) are shown as a ratio of each of the target cytokine genes compared with *gapdh* (fold change)*, statistically significant difference (*p* < 0.05 vs. control, student’s *t*-test, *n* = 3). NS, not significant; Cpn, *C. pneumoniae*; CNT, carbon nanotube; IL, interleukin; TNF, tumor necrosis factor.

**FIG 3.** Synergistic effect of *C. pneumoniae* with CNTs on IL-1β secretion from macrophages does not require bacterial growth or *de novo* bacterial protein synthesis. (A) Chlamydial growth in macrophages treated with or without CNTs. The *C. pneumoniae*-stimulated THP-1 cells were cultured during 3 days in the presence or absence of CNTs. The numbers of chlamydial (16S rDNA) and host cell DNA (*gapdh*) were monitored by qPCR.
and the data (average ± standard deviations) show a ratio of chlamydial 16S rDNA: gapdh. NS, Not significant; Cpn; C. pneumoniae. (B) Effect of de novo protein synthesis by C. pneumoniae on IL-1β secretion from macrophages. The C. pneumoniae-stimulated THP-1 cells treated with CNTs were cultured during 24 hours in the presence or absence of chloramphenicol (50 µg/ml) (the solvent control, EtOH), and IL-1β secretion was detected by Western blotting analysis. CP, chloramphenicol. sup, desalinated culture supernatants of THP-1 cells; cell; the remaining cells; Cpn, C. pneumoniae; CNT, CNTs.

**FIG 4.** Synergistic effect of *Chlamydia pneumoniae* with CNTs on IL-1β secretion from macrophages requires uptake of bacteria into cells, but not lysosomal maturation. (A) Cells stimulated with or without *C. pneumoniae* in the presence of absence of CNTs were incubated with either 2 µM cytochalasin D (actin polymerization inhibitor) or 50 nM bafilomysin A1 (vacuolar H-ATPase inhibitor) for 24 hours, and then IL-1β secretion from macrophages was detected. Results are representative of three independent experiments. (B) Representative transmission electron microscopy image reveals uptake of *C. pneumoniae* with CNTs into a macrophage. The square surrounded by bold line is enlarged in the right panel. N, nucleus. Arrows, CNTs. Arrowhead, *C. pneumoniae*. sup, desalinated culture supernatants of THP-1 cells; cell, the remaining cells; CD, cytochalasin D; BAF, bafilomysin A1; Cpn; *C. pneumoniae*; CNT, carbon nanotube; DMSO, dimethyl sulfoxide; IL, interleukin.

**FIG 5.** Synergistic effect of *Chlamydia pneumoniae* with CNTs on IL-1β secretion from macrophages is blocked by treatment with caspase inhibitors. (A) Cells stimulated with or without *C. pneumoniae* in the presence of absence of CNTs were incubated with either 10 µM z-VAD-FMK (pan-caspase inhibitor) or 10 µM z-WHED-FMK (caspase-1 inhibitor) for 24
hours, and then IL-1β secretion from macrophages was detected. Results are representative of three independent experiments. (B) Dose-dependent inhibition of IL-1β secretion from macrophages by the treatment with z-WHED-FMK. sup, desalinized culture supernatants of THP-1 cells; cell, the remaining cells; VAD, z-VAD-FMK; WHED, z-WHED-FMK; Cpn; C. pneumoniae; CNT, carbon nanotube; DMSO, dimethyl sulfoxide; IL, interleukin; LPS, lipopolysaccharide.

FIG 6. Synergistic effects of C. pneumoniae with CNTs on IL-18 secretion from macrophages. (A) IL-18 secretion was significantly increased by co-stimulation of C. pneumoniae with CNTs after incubation as compared to that of either CNTs or C. pneumoniae alone. The data are shown as average ± standard deviations. *, statistically significant difference ($p < 0.05$, student-t test, $n=3$). NS, not significant; Cpn; C. pneumoniae. CNT; CNTs. (B) Dose- and time-course experiments reveals that the synergistic increase of IL-18 secretion occurred in a time-dependent manner of the incubation. (C) Dose-dependent inhibition of IL-18 secretion from macrophages by the treatment with z-WHED-FMK. ND, not detected. See above.

FIG 7. Synergistic effect of Chlamydia pneumoniae with CNTs on IL-1β secretion from macrophages requires NLRP3 inflammasome activation followed by caspase-1 activation. (A) Gene silencing of nlrp3 knockdown (KD) (siRNA) and control (scrambled) cells was confirmed by RT-PCR. (B) Representative western blotting images show siRNA treatment diminished IL-1β secretion from NLRP3 KD cells stimulated with C. pneumoniae and/or CNTs. Results are representative of three independent experiments. sup, desalinized culture supernatants of THP-1 cells; cell, the remaining cells; RT, reverse transcription; Cpn, C. pneumoniae; CNT, carbon nanotube; IL, interleukin; NC, negative control.
FIG 8. NLRP3 inflammasome activation requires three distinct upstream signals, K⁺ efflux, lysosomal degradation, and ROS production. Cells stimulated with or without *Chlamydia pneumoniae* in the presence of absence of CNTs were incubated with either 70 mM KCl, 10 µM Ca-074 Me (cathepsin B inhibitor), or ROS inhibitors (5 mM NAC or 10 µM DPI) for 24 hours, and then IL-1β secretion from macrophages was detected. Treatment with (A) KCl, (B) CA or (C) DPI, but not NAC, blocked IL-1β secretion. Results are representative of three independent experiments. Cpn, *C. pneumoniae*. CNT, carbon nanotube; IL, interleukin; LPS, lipopolysaccharide; DMSO, dimethyl sulfoxide; ROS, reactive oxygen species.

FIG 9. Hypothetical model of synergistic effect of CNTs on IL-1β secretion from *C. pneumoniae*-infected macrophages. Cpn, *C. pneumoniae*; CNT, carbon nanotube; IL, interleukin.
Fig. 2

**IL-1β**

![Graph showing fold increase in IL-1β levels across different conditions: Cpn vs. CNT.](image)

**IL-8**

![Graph showing fold increase in IL-8 levels across different conditions: Cpn vs. CNT.](image)

**TNFα**

![Graph showing fold increase in TNFα levels across different conditions: Cpn vs. CNT.](image)
Fig. 4

A

<table>
<thead>
<tr>
<th></th>
<th>Cpn</th>
<th>Cpn + CNT</th>
<th>LPS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DMSO</td>
<td>CD</td>
<td>BFA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>sup</th>
<th>pro IL-1β</th>
<th>IL-1β</th>
</tr>
</thead>
<tbody>
<tr>
<td>cell</td>
<td>pro IL-1β</td>
<td>tubulin</td>
</tr>
</tbody>
</table>

B

[Image of cellular structures with annotations]
Fig. 5

[Image of a Western blot analysis showing the expression of pro IL-1β and IL-1β in the supernatant (sup) and cell lysate (cell) under different treatment conditions: Cpn, Cpn + CNT, LPS, DMSO, VAD, WHED, and ATP.]
Fig. 7

A

<table>
<thead>
<tr>
<th></th>
<th>scrambled</th>
<th>siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT−</td>
<td>RT+</td>
<td>RT−</td>
</tr>
</tbody>
</table>

- nlrp3
- gapdh

B

<table>
<thead>
<tr>
<th></th>
<th>Cpn</th>
<th>Cpn + CNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>scrambled</td>
<td>siRNA</td>
<td>scrambled</td>
</tr>
<tr>
<td>sup</td>
<td>pro IL-1β</td>
<td>IL-1β</td>
</tr>
<tr>
<td>cell</td>
<td>pro IL-1β</td>
<td>tubulin</td>
</tr>
</tbody>
</table>
Signal pathway: CNT

Signal pathway: Cpn